EDITORIAL COMMENTARY
Invasive Pneumococcal Disease 3 Years After the Introduction of the 13-Valent Conjugate Vaccine in the Oxfordshire Region of England Tina Q. Tan Feinberg School of Medicine, Northwestern University, and Division of Infectious Diseases, Ann and Robert H. Lurie Children’s Hospital, Chicago, Illinois
(See the major article by Moore et al on pages 1001–11.)
invasive pneumococcal disease; 13-valent pneumococcal conjugate vaccine.
Streptococcus pneumoniae is the leading bacterial cause of meningitis, bacteremia, and pneumonia in the United States and worldwide. With the licensure of a heptavalent pneumococcal conjugate vaccine (PCV7) in February 2000 and recommendations for its use in all children aged 2–23 months in the United States, the rate of invasive pneumococcal disease (IPD) among US children
Invasive Pneumococcal Disease 3 Years After the Introduction of the 13-Valent Conjugate Vaccine in the Oxfordshire Region of England Tina Q. Tan Feinberg School of Medicine, Northwestern University, and Division of Infectious Diseases, Ann and Robert H. Lurie Children’s Hospital, Chicago, Illinois
(See the major article by Moore et al on pages 1001–11.)
invasive pneumococcal disease; 13-valent pneumococcal conjugate vaccine.
Streptococcus pneumoniae is the leading bacterial cause of meningitis, bacteremia, and pneumonia in the United States and worldwide. With the licensure of a heptavalent pneumococcal conjugate vaccine (PCV7) in February 2000 and recommendations for its use in all children aged 2–23 months in the United States, the rate of invasive pneumococcal disease (IPD) among US children
